Iman Satti

Iman Satti

Postdoctoral Researcher

The Jenner Institute, University of Oxford, UK

Email: Iman.Satti@ndm.ox.ac.uk

 

 

 

 

VALIDATE Role:

Network Associate

 

Research Keywords: 

Host-Immune Responses, TB Vaccines, Correlates of Risk, Immunomonitoring

 

Biography:

My work focuses on studying host immune responses to new TB vaccines and correlates of risk of TB disease and infection. My research involves developing and establishing novel immunmonitoring techniques for evaluation of lung mucosal and systemic immunogenicity of candidate TB vaccines in humans.
 

In relation to new vaccine development, I am investigating possible mechanisms underlying declining vaccines’ immunogenicity in TB endemic areas compared to studies in the UK, this include a range of T and B cells markers, and also investigating the role of prior exposure to non-tuberculous mycobacteria.

 

Related Websites: 

The Jenner Institute Profile

LinkedIn Profile

 

Key Publications:

  • Iman Satti, Joel Meyer, Stephanie A. Harris, Zita-Rose Manjaly, Kristin Griffiths, Richard Antrobus, Rosalind Rowland, Henry Bettinson and Helen McShane. Immunogenicity of aerosol and intradermal MVA85A in the lungs and peripheral blood of healthy BCG-vaccinated UK adults (Lancet Infectious Diseases. Lancet Infect Dis. 2014 Oct;14(10):939-46.
  • Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,
  • Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290.
  • Matsumiya M, Satti I, Chomka A, Harris SA, Stockdale L, Meyer J, Fletcher HA, McShane H. Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model. J Infect Dis. 2015 May 1;211(9):1499-509. doi: 10.1093/infdis/jiu615. Epub 2014 Nov 7.
  • Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan S, Stockdale L,Manjaly Thomas ZR, Lopez-Ramon R, Poulton I, Lawrie A, Vermaak S, Le Vert A, Del Campo J, Hill F, Moss P, McShane H. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.Vaccine. 2016 Mar 8;34(11):1412-21. doi: 10.1016/j.vaccine.2016.01.062. Epub 2016 Feb 5.
  • Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, et al. Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination. The Journal of infectious diseases. 2013. Epub 2013/11/26.
  • Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013;31(7):1026-33. Epub 2012/12/26.
  • Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. The Journal of infectious diseases. 2012;205(7):1035-42. Epub 2012/03/08.